Tegsedi FDA Approval History
FDA Approved: Yes (First approved October 5, 2018)
Brand name: Tegsedi
Generic name: inotersen
Dosage form: Injection
Company: Ionis Pharmaceuticals, Inc.
Treatment for: Amyloidogenic Transthyretin Amyloidosis
Tegsedi (inotersen) is an antisense oligonucleotide inhibitor of the transthyretin (TTR) protein for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Development Timeline for Tegsedi
|Oct 5, 2018||FDA Approves Tegsedi (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis|
|Jan 8, 2018||Ionis' Inotersen NDA Accepted for Priority Review by the FDA|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.